Resources

MDoutlook® Delivers Precision Intelligence

Shaping your brand strategy is likely on your mind 24/7, and almost 365 days in the year. A recent case study from MDoutlook reviews how a focused approach to disease intelligence critically defines a roadmap for strategic brand decisions moving forward. Customer Global pharmaceutical company, currently with therapeutics in Hepato-Cellular
Read more
Strategic planning is a most critical aspect of managing a product or portfolio. Often there are gaps in the internal knowledge base to make important decisions. With our institutional knowledge of oncology, proprietary access to the largest global database of cancer treaters, and hundreds of oncology intelligence projects successfully delivered,
Read more
MDoutlook proudly continues our innovative initiative of syndicated research analyzing the clinical impact of new data presented at the 2016 ASCO Annual Meeting®. Supporting the entire cancer community and building on nearly 40 analyses since 2008, this is the fourth and final report for our 2016 series covering new data
Read more
MDoutlook presents the results from our innovative initiative of syndicated research gauging the clinical impact of new data presented at the 2016 ASCO Annual Meeting®. Supporting the entire cancer community and building on nearly 40 analyses since 2008, this is the third of four reports in our 2016 series covering
Read more
MDoutlook proudly continues our innovative initiative of syndicated research analyzing the clinical impact of new data presented at the 2016 ASCO Annual Meeting®. Supporting the entire cancer community and building on nearly 40 analyses since 2008, this is the second of four reports in our 2016 series covering news presented
Read more
MDoutlook proudly continues our innovative initiative of syndicated research analyzing the clinical impact of new data presented at the 2016 ASCO Annual Meeting®. Supporting the entire cancer community and building on nearly 40 analyses since 2008, this is the first report in our 2016 series covering new clinical data presented
Read more
Before the 2016 ASCO Annual Meeting® started, we asked oncologists about which tracks they were most excited. With the annual neeting behind us, we followed up to find out which tracks actually delivered on that excitement. Included in our Post-Chicago OncoPoll™ were a few questions: “Did you attend this year’s
Read more
With another meeting of the American Society of Clinical Oncology® behind us, the MDoutlook disease analyst team is set to launch our 8th annual OncoPoll™ series measuring the immediate clinical impact of new data presented at the 2016 Annual Meeting in Chicago. The largest gathering of cancer treaters in the
Read more
Almost all of the recent buzz in oncology is focused on the 2016 ASCO Annual Meeting®, which is starting this Friday in Chicago. In order to see how this information is being received by oncologists, we asked our panel of physicians a simple 2-question survey: “Are you planning to attend
Read more
The National Cancer Moonshot Initiative, announced by President Obama in January, is gaining momentum. "We are at an inflection point, and the science is ready for the concerted new effort this initiative will deliver. Cancer is now known to be hundreds of diseases, each with unique features, driving forces, and
Read more
Shaping your brand strategy is likely on your mind 24/7, and almost 365 days in the year. A recent case study from MDoutlook reviews how a focused approach to disease intelligence critically defines a roadmap for strategic brand decisions moving forward. Customer Global pharmaceutical company, currently with therapeutics in Hepato-Cellular
Read more
Strategic planning is a most critical aspect of managing a product or portfolio. Often there are gaps in the internal knowledge base to make important decisions. With our institutional knowledge of oncology, proprietary access to the largest global database of cancer treaters, and hundreds of oncology intelligence projects successfully delivered,
Read more
MDoutlook proudly continues our innovative initiative of syndicated research analyzing the clinical impact of new data presented at the 2016 ASCO Annual Meeting®. Supporting the entire cancer community and building on nearly 40 analyses since 2008, this is the fourth and final report for our 2016 series covering new data
Read more
MDoutlook presents the results from our innovative initiative of syndicated research gauging the clinical impact of new data presented at the 2016 ASCO Annual Meeting®. Supporting the entire cancer community and building on nearly 40 analyses since 2008, this is the third of four reports in our 2016 series covering
Read more
MDoutlook proudly continues our innovative initiative of syndicated research analyzing the clinical impact of new data presented at the 2016 ASCO Annual Meeting®. Supporting the entire cancer community and building on nearly 40 analyses since 2008, this is the second of four reports in our 2016 series covering news presented
Read more
MDoutlook proudly continues our innovative initiative of syndicated research analyzing the clinical impact of new data presented at the 2016 ASCO Annual Meeting®. Supporting the entire cancer community and building on nearly 40 analyses since 2008, this is the first report in our 2016 series covering new clinical data presented
Read more
Before the 2016 ASCO Annual Meeting® started, we asked oncologists about which tracks they were most excited. With the annual neeting behind us, we followed up to find out which tracks actually delivered on that excitement. Included in our Post-Chicago OncoPoll™ were a few questions: “Did you attend this year’s
Read more
With another meeting of the American Society of Clinical Oncology® behind us, the MDoutlook disease analyst team is set to launch our 8th annual OncoPoll™ series measuring the immediate clinical impact of new data presented at the 2016 Annual Meeting in Chicago. The largest gathering of cancer treaters in the
Read more
Almost all of the recent buzz in oncology is focused on the 2016 ASCO Annual Meeting®, which is starting this Friday in Chicago. In order to see how this information is being received by oncologists, we asked our panel of physicians a simple 2-question survey: “Are you planning to attend
Read more
The National Cancer Moonshot Initiative, announced by President Obama in January, is gaining momentum. "We are at an inflection point, and the science is ready for the concerted new effort this initiative will deliver. Cancer is now known to be hundreds of diseases, each with unique features, driving forces, and
Read more